- Global Pharma News & Resources

Competitive Landscape of the Multiplex Assays Market: Key Players and Strategies

Competitive Landscape of the Multiplex Assays Market: Key Players and Strategies


multiplex assays market is valued at an estimated USD 3.5 billion in 2022 and is projected to reach USD 5.3 billion by 2027, at a CAGR of 8.8%
Editor: Jignesh Jariwala Last Updated: 04-Sep-2023


In recent years, the healthcare and biotechnology industries have witnessed a paradigm shift with the introduction of cutting-edge technologies. One such breakthrough is the Multiplex Assays Market, which has revolutionized the way researchers conduct various diagnostic and research applications. This article aims to provide an in-depth overview of the Multiplex Assays Market, exploring its significance, applications, advantages, and potential for the future.

"Multiplex Assays Market by Product & Service (Consumables, Instruments, Software & Services), Type (Nucleic Acid, Protein), Technology (Flow Cytometry, Luminescence), Application (R&D, Diagnosis), End User (Pharma, Hospitals) - Global Forecast to 2027", is valued at an estimated USD 3.5 billion in 2022 and is projected to reach USD 5.3 billion by 2027, at a CAGR of 8.8%

What is the Multiplex Assays Market?

The Multiplex Assays Market refers to the use of multiplexing technology in the simultaneous detection and analysis of multiple analytes in a single experiment. By combining multiple assays into one, researchers can efficiently analyze complex biological samples, saving time, and reducing costs. This technology has found applications in various fields, including clinical diagnostics, drug discovery, genomics, proteomics, and more.

The key players in multiplex assays market are Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), DiaSorin S.p.A. (Italy), QIAGEN N.V. (Netherlands), Abcam plc (UK), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Quanterix (US), Bio-Techne (US), MESO SCALE DIAGNOSTICS, LLC (US), Randox Laboratories Ltd. (UK), Olink (Sweden), Seegene Inc. (South Korea), Siemens Healthcare AG (Germany), PerkinElmer Inc. (US), Shimadzu Corporation (Japan), Promega Corporation (US), Enzo Biochem Inc. (US), Cayman Chemical (US), Boster Biological Technology (US), Antigenix America, Inc. (US), Quansys Biosciences Inc. (US), and RayBiotech Life, Inc. (US).

Download a PDF Brochure:

In 2021, Illumina, Inc. held the leading position in the multiplex assays market. The company has a strong geographic presence across the US, Europe, Greater China, and the Asia Pacific. The company focuses on offering consumables and analyzers in the multiplex assays market. Illumina concentrates on inorganic strategies to maintain its leadership position in this market. The company has signed several collaborations and partnerships with other companies/organizations, which are expected to strengthen the foothold of the company in the domain of next-generation sequencing (NGS) and multiplex sequencing. With such developments and strategic efforts, the company is expected to witness growth during the forecast period.

Bio-Rad Laboratories, Inc. is a leading player in the multiplex assays market. Its leading position in this market can be attributed to its strong global sales and distribution network, enabling it to effectively market its products in various countries. The company has a wide geographical presence in the US, Singapore, China, the UK, Belgium, Switzerland, France, and Germany. The company has strong R&D and manufacturing in the area of specialty chemicals and clinical diagnostics. The company has received the EUA from the US FDA for several COVID-19 multiplex assays, including SARS-CoV-2 Droplet Digital PCR (ddPCR) test kit and SARS-CoV-2 Total Ab test in 2021. Such product launches have helped the company significantly expand its product line and enhance its multiplex assays market visibility.

Thermo Fisher Scientific, Inc. is a leading player in the multiplex assays market. The company has a strong geographic presence in over 600 locations across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. With a strong focus on R&D and competitive technologies, Thermo Fisher continuously strives for innovation.

Advantages of Multiplex Assays

Enhanced Efficiency: Multiplex assays enable the simultaneous analysis of numerous analytes, optimizing laboratory workflow and significantly reducing assay time.

Cost-effectiveness: By combining multiple tests into one, the Multiplex Assays Market reduces reagent consumption, leading to cost savings in both research and clinical settings.

Conservation of Sample Volume: Researchers can analyze multiple biomarkers using small sample volumes, making it ideal for situations where sample availability is limited.

Highly Informative Data: The comprehensive data generated by multiplex assays provides a more detailed understanding of complex biological processes and disease pathways.

Streamlined Data Analysis: Multiplex assays utilize advanced software and algorithms, simplifying data interpretation and analysis.

Request a Sample Report:

Applications of Multiplex Assays

Clinical Diagnostics

In clinical diagnostics, the Multiplex Assays Market has transformed patient care by enabling the rapid and accurate detection of multiple disease markers from a single patient sample. This technology has proved invaluable in diagnosing infectious diseases, cancer, autoimmune disorders, and cardiovascular conditions.

Drug Discovery

The pharmaceutical industry has embraced multiplex assays for drug discovery and development. Researchers can efficiently screen drug candidates against multiple targets simultaneously, identifying potential candidates more effectively.

Genomics and Proteomics

Multiplex assays have accelerated genomics and proteomics research by enabling the simultaneous analysis of multiple genes, proteins, and biomolecules. This advancement has contributed to a deeper understanding of diseases and the identification of potential therapeutic targets.

Overcoming Challenges

Despite the tremendous benefits, the Multiplex Assays Market faces certain challenges. Cross-reactivity between analytes, assay standardization, and data analysis complexities are some hurdles that researchers and manufacturers are actively working to overcome.


Q1: How does multiplex technology work?

Multiplex technology employs microspheres or microarrays, each with unique capture probes specific to a target analyte. When a sample is introduced, the probes capture their corresponding analytes, allowing for simultaneous analysis.

Is multiplex assay only used in research?

No, multiplex assays have gained significant popularity in clinical diagnostics and drug discovery. They are widely employed in research, clinical laboratories, and the pharmaceutical industry.

What are the future prospects for the Multiplex Assays Market?

The future of the Multiplex Assays Market is highly promising, with ongoing advancements in technology and expanding applications across various industries.


The Multiplex Assays Market has emerged as a game-changer in the fields of research, diagnostics, and drug discovery. Its ability to analyze multiple analytes simultaneously offers tremendous advantages, leading to improved efficiency and cost savings. As technology continues to evolve, we can expect the Multiplex Assays Market to unlock even more exciting possibilities for enhancing human health and advancing scientific knowledge.